Publications by authors named "Yun-Li Huang"
Background: According to GLOBOSCAN, hepatocellular carcinoma (HCC) claimed 782,000 lives in 2018. The tyrosine kinase inhibitor sofafenib is used to treat HCC, but new anticancer agents targeting different pathways are urgently needed to improve outcomes for patients with advanced disease. The aberrant metabolism and aggressive growth of cancer cells can render them particularly susceptible to proteasome inhibition, as demonstrated by bortezomib treatment of multiple myeloma.
View Article and Find Full Text PDFObjective: This study was performed to assess the effect of artemisinin against isoflurane-induced neuronal apoptosis and cognitive impairment in neonatal rats.
Methods: Artemisinin (50, 100 or 200 mg/kg b.wt/day; oral gavage) was administered to separate groups of neonatal rats starting from postnatal day 3 (P3) to postnatal day 21 (P21).
Background: Oral Candida colonization and its relation with predisposing factors in HIV-infected patients have received wide concerns during recent decades. In this study, we investigated asymptomatic oral Candida carriage rate, species distribution and antifungal susceptibility of 604 HIV-infected patients and 851 healthy individuals in Kunming, Yunnan Province of China.
Methods: Mucosal swab sampling was taken from each subject and CHROMagar Candida agar medium and API 20C AUX system were used to identify yeast isolates.
[The characteristic of T cells response to HBV-specific antigen proteins in patients with HBV infection].
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi
August 2012
Article Synopsis
- The study aimed to analyze T cell responses to specific hepatitis B virus proteins among four patient groups: acute hepatitis B (AHB), active chronic hepatitis B (CHB), inactive HBV carriers (AsC), and those with past infections.
- Results showed no significant differences in T cell frequencies for HBsAg, HBcAg, and HBeAg between AHB and CHB. However, frequencies were lower in AsC and past infection groups compared to AHB and CHB.
- The study concluded that AsC had the highest T cell response to HBeAg, while other groups showed the strongest responses to HBcAg, suggesting varying immune responses depending on the phase of HBV infection.
Objective: To investigated the impact of viral load decline on virus-specific T-cell reactivity on patients with chronic hepatitis B.
Methods: 23 cases of patients with chronic hepatitis B were recruited randomized to therapy with nucleoside analogue or alpha interferon from January 2009 to April 2010. Peripheral blood mononuclear cells (PBMCs) were collected longitudinally at baseline and the time of HBV DNA undetected.
[Clinical characteristics of drug-induced liver injury in 31 pediatric cases].
Zhonghua Gan Zang Bing Za Zhi
March 2012
Objective: To investigate the clinical characteristics and responsible agents of drug-induced liver injury (DILI) in pediatric patients.
Methods: Thirty-one cases of DILI treated in our hospital's pediatric ward were retrospectively analyzed. The clinical data for each patient were extracted from the patient's medical records, and included reported causes, physical and biochemical features, natural history, blood examination results, and hepatic pathology findings.
[Clinical significance of liver function and autoantibodies in patients with acute or chronic drug-induced liver injury].
Zhonghua Gan Zang Bing Za Zhi
January 2010
Objective: To investigate the clinical significance of liver function and autoantibodies in patients with acute or chronic drug-induced liver injury.
Methods: 51 patients with drug-induced liver injury were divided into acute drug induced liver injury group and chronic drug induced liver injury group, liver function and autoantibodies were compared between these two groups.
Results: There was no significant difference (P more than 0.
Article Synopsis
- The study aimed to identify genetic variations (SNPs) in the MxA protein and eIF-2a-reg2 and assess how these variations predict the response to interferon treatment in patients with chronic hepatitis B.
- Out of 262 patients treated with interferon alfa, 19.1% demonstrated a sustained therapeutic response, particularly those with the GT genotype at the MxA promoter -88, which was linked to a significantly higher treatment response.
- The findings suggest that specific SNPs, especially at the MxA promoter -88, could serve as useful markers for predicting treatment effectiveness in chronic hepatitis B patients.